Santen was founded in 1890 in Osaka, Japan, and is a global pharmaceutical company dedicated exclusively to ophthalmology. Guided by its vision “Happiness with Vision”, Santen focuses on improving eye health and quality of life for people worldwide. The company now supports the eye health of people in over 60 countries and regions, combining more than 135 years of scientific and clinical expertise. Santen’s business centers on prescription ophthalmic pharmaceuticals, which form the majority of its revenue, supported by OTC eye care and surgical/medical devices.
Its diverse portfolio covers dry eye, glaucoma, infection, allergy, age related macular degeneration & Myopia reflecting strong leadership in eye care. The company’s R&D strategy focuses on addressing unmet medical needs, improving development success rates, and accelerating time to launch. Current pipeline priorities in Asia span Myopia, Presbyopia, Ptosis and Retinitis Pigmentosa (RP), alongside lifecycle management of cornerstone brands. Santen’s Medium Term Plan emphasizes steady and profitable global growth, patient centric approach to delivering optimal ophthalmic care, and strategic capital allocation to build foundations for mid- to long- term growth.
In Asia Pacific, Santen maintains a strong presence with Singapore as a regional hub supporting commercial, medical, and operational functions across ASEAN and greater Asia. The region plays a critical role in expanding access to innovative treatments and strengthening partnerships with healthcare professionals. Santen is also committed to global sustainability through responsible governance, ethical business practices, and initiatives that promote long term eye care accessibility. With its deep scientific heritage, focused expertise, and expanding global footprint, Santen continues to drive meaningful innovation in ophthalmology – advancing vision care for patients worldwide.
Contact Details:
Name: Kamonwan Damrongphiwat (Ice)
Email: kamonwan.damrongphiwat@santen.com